Corcept Therapeutics Q2 revenue estimates, raises 2026 outlook

Corcept Therapeutics Incorporated

29/07/2026 21:13

Overview
U.S. biopharma firm's Q2 revenue rose 32% yr/yr, beating analyst expectations
Net income for Q2 increased to $43.0 mln from $35.1 mln last year
Company raised 2026 revenue guidance to $1.1–$1.2 bln

Outlook
Corcept raises 2026 revenue guidance to $1.1–$1.2 bln
Company expects FDA decision on relacorilant for Cushing’s syndrome by Dec 17, 2026
Corcept anticipates results from key clinical trials by end of 2026 and 2027

Result Drivers
LIFYORLI LAUNCH - Q2 benefited from initial sales of Lifyorli, with over 1,300 patients starting treatment since its FDA approval in March 2026
CUSHING’S SYNDROME PRESCRIPTIONS - Record new prescriptions for Korlym and its authorized generic, attributed to increased physician recognition of hypercortisolism’s prevalence and need for treatment
OPERATING EXPENSES - Higher operating expenses driven by Lifyorli launch and investments in Cushing’s syndrome business

Company press release: ID:nBwbxZl04a

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$256.15 mln
$221.82 mln (3 Analysts)
Q2 EPS
 
$0.36
 
Q2 Net Income
 
$42.99 mln
 

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy", no "hold" and 1 "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Corcept Therapeutics Inc is $91.50, about 2.9% below its July 28 closing price of $94.19
The stock recently traded at 51 times the next 12-month earnings vs. a P/E of 52 three months ago

Reuters Recommended Reads
July 29 - Biogen beats quarterly estimates as newer drugs drive growth
July 29 - Processa buys Vidya Therapeutics, raises $200 million for drug trials
July 28 - Incyte lifts annual revenue forecast after settlement with CMS

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)